Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 20502631)

1.

Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture.

Silberstein E, Mihalik K, Ulitzky L, Plant EP, Puig M, Gagneten S, Yu MY, Kaushik-Basu N, Feinstone SM, Taylor DR.

PLoS Pathog. 2010 May 20;6(5):e1000910. doi: 10.1371/journal.ppat.1000910.

2.

The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism.

Tsai YH, Kuang WF, Lu TY, Kao JH, Lai MY, Liu CJ, Chen PJ, Hwang LH.

J Hepatol. 2008 Dec;49(6):899-907. doi: 10.1016/j.jhep.2008.06.030. Epub 2008 Sep 16.

PMID:
18842320
3.

Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta.

Hiasa Y, Kuzuhara H, Tokumoto Y, Konishi I, Yamashita N, Matsuura B, Michitaka K, Chung RT, Onji M.

Hepatology. 2008 Jul;48(1):59-69. doi: 10.1002/hep.22289.

PMID:
18459156
4.

Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.

Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C.

Hepatology. 1997 Mar;25(3):750-3.

PMID:
9049230
5.
6.

Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems.

Gottwein JM, Bukh J.

Adv Virus Res. 2008;71:51-133. doi: 10.1016/S0065-3527(08)00002-X. Review.

PMID:
18585527
7.

Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.

Karino Y, Toyota J, Sugawara M, Higashino K, Sato T, Ohmura T, Suga T, Okuuchi Y, Matsushima T.

Am J Gastroenterol. 1997 Jan;92(1):61-5.

PMID:
8995939
8.

Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients.

Missale G, Cariani E, Lamonaca V, Ravaggi A, Rossini A, Bertoni R, Houghton M, Matsuura Y, Miyamura T, Fiaccadori F, Ferrari C.

Hepatology. 1997 Sep;26(3):792-7.

PMID:
9303515
9.

Pathogenesis, diagnosis and management of hepatitis C.

Boyer N, Marcellin P.

J Hepatol. 2000;32(1 Suppl):98-112. Review.

PMID:
10728798
10.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG.

Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.

PMID:
20410884
12.

Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a.

Okamoto H, Mishiro S, Tokita H, Tsuda F, Miyakawa Y, Mayumi M.

Hepatology. 1994 Nov;20(5):1131-6.

PMID:
7927243
13.

Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.

Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D.

J Virol. 1998 Apr;72(4):2795-805.

14.

Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.

Chen CM, He Y, Lu L, Lim HB, Tripathi RL, Middleton T, Hernandez LE, Beno DW, Long MA, Kati WM, Bosse TD, Larson DP, Wagner R, Lanford RE, Kohlbrenner WE, Kempf DJ, Pilot-Matias TJ, Molla A.

Antimicrob Agents Chemother. 2007 Dec;51(12):4290-6. Epub 2007 Oct 1.

15.

Prompt decrease of circulating hepatitis C virus in patients with chronic hepatitis C after treatment with interferon.

Saitoh H, Naitoh S, Okamoto H, Akahane Y.

J Interferon Res. 1994 Oct;14(5):239-44.

PMID:
7532200
16.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.

J Clin Virol. 2012 Aug;54(4):352-4. doi: 10.1016/j.jcv.2012.04.024. Epub 2012 Jun 1.

PMID:
22658798
17.

Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection.

Fernández I, Castellano G, Domingo MJ, Fuertes A, Colina F, Canga F, de la Cruz FJ, de la Cámara AG, Solís JA.

Scand J Gastroenterol. 1997 Jan;32(1):70-6.

PMID:
9018770
18.

Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.

Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, Mitamura K.

Am J Gastroenterol. 2003 Jun;98(6):1377-83.

PMID:
12818284
19.

Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo.

Zeuzem S, Schmidt JM, Lee JH, Rüster B, Roth WK.

Hepatology. 1996 Feb;23(2):366-71.

PMID:
8591865
20.

Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load.

Arase Y, Suzuki F, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Kobayashi M, Sezaki H, Ikeda K, Kumada H.

Intervirology. 2004;47(1):19-25.

PMID:
15044832
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk